{"id":"W3089255874","doi":"10.1016/j.annonc.2020.08.790","title":"718P A phase II study of patients with advanced or metastatic renal cell carcinoma (mRCC) receiving pazopanib after previous checkpoint inhibitor treatment","year":2020,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Renal cell carcinoma treatment","field":"Medicine","cited_by":15,"is_retracted":false,"has_abstract":false,"ca_institutions":"University of Calgary","funders":"NIH Clinical Center; Universitätsklinikum Essen; Queen Mary University of London; Novartis Pharmaceuticals Corporation; Massachusetts General Hospital","keywords":"Medicine; Pazopanib; Clinical endpoint; Internal medicine; Renal cell carcinoma; Oncology; Progression-free survival; Phases of clinical research; Tyrosine-kinase inhibitor; Toxicity; Chemotherapy; Urology; Surgery; Sunitinib; Clinical trial; Cancer","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0008089418,0.001102564,0.002216002,0.0003324974,0.0005178013,0.0009855255,0.0005704241,0.0009386149,0.004549393],"category_scores_gemma":[0.0007141617,0.0004606314,0.001487521,0.0004154403,0.0006840168,0.0007530815,0.0003210776,0.003096464,0.0009973239],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0009095819,"about_ca_system_score_gemma":0.001756858,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.002084292,"about_ca_topic_score_gemma":0.004789779,"domain_scores_codex":[0.9996462,0.0001219835,0.00001253522,0.00007610942,0.0000283058,0.0001148502],"domain_scores_gemma":[0.9993792,0.0001030325,0.00006705163,0.00003675531,0.00003618385,0.000377752],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.8497391,0.03848214,0.01315499,0.0005186443,0.001686838,0.0004410055,0.0001667164,0.002065925,0.02210427,0.0002262127,0.005298065,0.06611603],"study_design_scores_gemma":[0.5424105,0.4156522,0.03342943,0.00003250695,0.0009066697,0.000433758,0.00009735949,0.001268264,0.001628878,0.0002536157,0.003844153,0.00004276537],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9948756,0.0008451446,0.0001633639,0.0003474984,0.0001309079,0.0007162829,0.001137464,0.00004150771,0.001742232],"genre_scores_gemma":[0.9888262,0.001288706,0.000636845,0.0007126394,0.0001841766,0.001023412,0.003536979,0.00002257537,0.003768511],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.004549393,"threshold_uncertainty_score":0.01521921,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.07611631056768055,"score_gpt":0.3484757106725119,"score_spread":0.2723594001048314,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}